期刊文献+

新型医院药学服务助力慢性鼻-鼻窦炎患者用药安全

New Hospital Pharmaceutical Care Helps the Drug Safety of Patients with Chronic Rhinosinusitis
下载PDF
导出
摘要 目的:评估新型医院药学服务对用药安全的影响。方法:纳入2019年至2020年九江市第一人民医院门诊就诊的慢性鼻-鼻窦炎患者196名,随机数字表法分为传统医院药学服务组(传统组)和新型医院药学服务组(新型组),传统组向患者提供药品调剂、处方审核及发药窗口用药交代等传统药学服务。新型组除传统药学服务外,还给予书面用药指导单并提供用药咨询。两组均通过随访填写问卷方式跟踪患者情况,记录观察指标,比较患者用药依从性及药物不良反应发生情况。结果:新型组不良反应发生率为3.06%,传统组不良反应发生率为13.27%,差异有统计学意义(P<0.05)。传统组依从率为91.84%。新型组依从率为100.00%,差异有统计学意义(P<0.05)。传统组病情控制率87.76%,新型组病情控制率98.98%,差异有统计学意义(P<0.05)。结论:新型的医院药学服务对慢性鼻-鼻窦炎患者用药安全的提升具有积极意义。 Objective:Evaluate the impact of new hospital pharmaceutical care on medication safety.Methods:196 patients with chronic rhinosinusitis treated in The First Peoples Hospital of Jiujiang outpatient department from 2019 to 2020 were prospectively included and randomly divided into traditional hospital pharmaceutical care group(traditional group)and new hospital pharmaceutical care group(new group).The traditional group provided patients with traditional pharmaceutical services such as drug dispensing,prescription review and drug delivery window.In addition to traditional pharmaceutical care,the new group was also given written medication guidance and medication consultation.Both groups followed up the patients by filling in questionnaires,recorded the observation indexes,and compared the medication compliance and adverse drug reactions.Results:The incidence of adverse reactions was 3.06%in the new group and 13.27%in the traditional group(P<0.05).The compliance rate of the traditional group was 91.84%.The compliance rate of the new group was 100.00%(P<0.05).The disease control rate was 87.76%in the traditional group and 98.98%in the new group(P<0.05).The incidence of adverse drug reactions in the new group was lower than that in the traditional group,while the medication compliance and disease control rate were higher than those in the traditional group.Conclusion:This study shows that the new hospital pharmaceutical care is of positive significance to improve the drug safety of patients with chronic rhinosinusitis,which is worthy of discussion and promotion.
作者 代晶 饶振华 沈娟娟 DAI Jing;RAO Zhenhua;SHEN Juanjuan(The First Peoples Hospital of Jiujiang,Jiujiang Jiangxi 332000,China)
出处 《药品评价》 CAS 2022年第6期355-358,共4页 Drug Evaluation
基金 江西省九江市科技计划项目(201819015)。
关键词 药学服务 鼻窦 依从性 不良反应 用药安全 Pharmaceutical care Rhinitis Compliance Adverse reactions Medication safety
  • 相关文献

参考文献11

二级参考文献146

共引文献1455

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部